Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 14:14:1104025.
doi: 10.3389/fendo.2023.1104025. eCollection 2023.

Pharmacological management of cherubism: A systematic review

Pierre-Emmanuel Cailleaux  1 , André Luís Porporatti  2 , Martine Cohen-Solal  3 , Natacha Kadlub  4 , Amélie E Coudert  5
Affiliations

Pharmacological management of cherubism: A systematic review

Pierre-Emmanuel Cailleaux et al. Front Endocrinol (Lausanne). .

Abstract

Objective: The aim of this systematic review was to determine if there exists an efficacious drug treatment for cherubism, based on published studies.

Methods: This systematic review included observational case studies reporting pharmacological management of cherubism. We developed specific search strategies for PubMed (including Medline), ScienceDirect, Web of Science. We evaluated the methodological quality of the included studies using criteria from the Joanna Briggs Institute's critical appraisal tools.

Results: Among the 621 studies initially identified by our search script, 14 were selected for inclusion, of which five were classified as having a low risk of bias, four as having an unclear risk, and five a high risk. Overall, 18 cherubism patients were treated. The sample size in each case study ranged from one to three subjects. This review identified three types of drugs used for cherubism management: calcitonin, immunomodulators and anti-resorptive agents. However, the high heterogeneity in case reports and the lack of standardized outcomes precluded a definitive conclusion regarding the efficacy of any treatment for cherubism.

Conclusions: The present systematic review could not identify an effective treatment for cherubism due to the heterogeneity and limitations of the included studies. However, in response to these shortcomings, we devised a checklist of items that we recommend authors consider in order to standardize the reporting of cherubism cases and specifically when a treatment is given toward identification of an efficacious cherubism therapy.

Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022351044, identifier CRD42022351044.

Keywords: cherubism; drug; management – healthcare; pharmacological treatment; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the literature search and selection criteria.
Figure 2
Figure 2
Patient distribution by age.
Figure 3
Figure 3
Risk of bias. (A) Risk of bias graph: review authors’ judgments about each risk of bias items presented as percentages across all included studies. (B) Risk of bias summary: review authors’ judgments about each risk of bias item for each included study.
See this image and copyright information in PMC

References

    1. Chrcanovic BR, Guimarães LM, Gomes CC, Gomez RS. Cherubism: a systematic literature review of clinical and molecular aspects. Int J Oral Maxillofac Surg (2021) 50:43–53. doi: 10.1016/j.ijom.2020.05.021 - DOI - PubMed
    1. Morbach H, Hedrich CM, Beer M, Girschick HJ. Autoinflammatory bone disorders. Clin Immunol (2013) 147:185–96. doi: 10.1016/j.clim.2012.12.012 - DOI - PubMed
    1. Von Wowern N. Cherubism: a 36-year long-term follow-up of 2 generations in different families and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2000) 90:765–72. doi: 10.1067/moe.2000.108438 - DOI - PubMed
    1. Papadaki ME, Lietman SA, Levine MA, Olsen BR, Kaban LB, Reichenberger EJ. Cherubism: Best clinical practice. Orphanet J Rare Dis (2012) 7:S6. doi: 10.1186/1750-1172-7-S1-S6 - DOI - PMC - PubMed
    1. Aloni MN, Kambere RS, Molua A, Dilu JN, Tshibassu PM, Kazadi-Lukusa A, et al. . Cherubism in sub-Saharan Africa: a first case-report in a child. Rare Tumors (2015) 7:5675. doi: 10.4081/rt.2015.5675 - DOI - PMC - PubMed

Publication types

LinkOut - more resources